PROTHENA CORP PLC (PRTA)
IE00B91XRN20 - Common Stock
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Prothena to Participate in Upcoming Healthcare Conferences
Prothena Appoints David Ford to Newly Created Chief People Officer Position
Prothena files to offer ordinary shares (NASDAQ:PRTA)
Prothena files prospectus for offering of ordinary shares without disclosing the amount. This is not an offer to sell securities.
Prothena appoints Daniel G. Welch as Chair Designate (NASDAQ:PRTA)
Prothena Corporation appoints Daniel G. Welch as an independent director and Chair Designate, with plans to elect him as Chair of the Board later this year.
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
Prothena GAAP EPS of -$1.26 misses by $0.03, revenue of $0.32M misses by $2.4M (NASDAQ:PRTA)
Prothena's Q4 financial results fall short as EPS and revenue miss expectations.
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
RSI Alert: Prothena (PRTA) Now Oversold
Prothena stock downgraded at Bank of America (NASDAQ:PRTA)
Prothena Corporation (PRTA) stock tumbles after Bank of America downgrades the Alzheimer's drug developer, citing delays in its R&D programs. Read more here.
Interesting PRTA Put And Call Options For January 2026
Prothena stock tumbles 23% in premarket trading (NASDAQ:PRTA)
Prothena (PRTA) stock tumbled 23% in premarket trading after the company released updates on its pipeline and cash position. Read more here.
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs
Notable Thursday Option Activity: FSLR, PRTA, CVNA
Noteworthy Tuesday Option Activity: PRTA, FWRD, FL
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Biotech companies are edging closer to finding the answers behind Alzheimer's disease.
Commit To Purchase Prothena At $30, Earn 65.2% Annualized Using Options
Prothena Reports Third Quarter 2023 Financial Results and Business Highlights
Noteworthy Monday Option Activity: SAVE, ALGM, PRTA
